Why is assessing the prognosis of NASH patients important?
In the United States, there is a need for a simple, noninvasive, prognostic test that is convenient, accurate, and widely accessible.
In this 5-minute video, Dr. Noureddin discusses why it’s important that a noninvasive test be prognostic, the current lack of noninvasive prognostic tests in NASH, the benefits of the new Enhanced Liver Fibrosis (ELF™) Test, and how he envisions use of the test in clinical practice.
About Mazen Noureddin
Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center (currently ranked #2 in GI and GI surgery per US News). Dr. Noureddin completed his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). There, he finished the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. In 2013, he joined the University of Southern California (USC) as an assistant professor of clinical medicine. He was recruited to Cedars-Sinai Medical Center in 2015 to establish its new Fatty Liver Program.
Dr. Noureddin’s focus is on clinical and translational research in the area of NAFLD/NASH and NASH-related cirrhosis. He conducted more than 40 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in noninvasive testing and biomarkers in the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. He has published in all these areas. He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD NASH special interest group education sub-committee and serves on the editorial board for the journals Clinical Gastroenterology and Hepatology (CGH) and Gastroenterology. He is also one of the new associate editors of Clinical Gastroenterology and Hepatology (CGH). He is funded by the National Cancer Institute. He has published in many journals, including The Lancet, Science Trinational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, Clinical Gastroenterology and Hepatology, and others.
